Oyster Point Pharma, Inc. (OYST) [Rocket]

In millions, except per share items	Dec-31-21	Dec-31-20	Dec-31-19	Dec-31-18	Dec-05-18	Dec-31-17
	10-K	10-K	10-K	10-K	8-K	S-1/A
Revenue:

License revenue - related party
Total revenue	24.5				13.8	3.6
Total revenue growth				-100.0%
Cost of product revenue	1.5

Operating expenses:
Sales and marketing	54.6	9.9
General and administrative	40.8	21.3	13.7	3.0	3.0	2.1
Research and development	24.2	39.8	33.6	13.8
Total operating expenses	119.7	71.0	47.3	16.7	16.7	5.7
Loss from operations	-96.7	-71.0	-47.3	-16.7	-16.7	-5.7
Operating margin	-393.9%

Other (expense) income, net
Interest expense	-3.7
Other income (expense), net	-0.3	0.5
Total other (expense) income, net	-4.0	0.5
Net loss	-100.7	-70.5	-45.7	-16.5

Net loss per share, basic (in dollars per share)	($3.87)	($2.92)	($9.97)	($11.69)	($11.69)	($13.56)
Net loss per share, diluted (in dollars per share)	($3.87)	($2.92)	($45,711,000.00)	($16,503,000.00)	($11.69)	($13.56)

Weighted average shares outstanding, basic (in shares)	26.0	24.1	4.6	1.4	1,412.0	1.4
Weighted average shares outstanding, diluted (in shares)	26.0	24.1

Product revenue, net [Extensible Enumeration]